echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Hengrui releases new findings on Carrelli Pearl monoantigen synocosis or will have immunotherapy

    Hengrui releases new findings on Carrelli Pearl monoantigen synocosis or will have immunotherapy

    • Last Update: 2020-06-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    ESCORT research is a randomized, open, chemotherapy drug control, multicenter Phase III clinical study, started in May 2017 in the group of patients, as of May 2019, a total of 448 patients randomly enrolled and received the study drug, of which 228 patients received Carlyzumab monotherapy, 220 patients received the researchers selected chemotherapyDetailed results of the study will be released simultaneously at the Chinese Society of Clinical Oncology (CSCO) and the Annual Meeting of the European Society of Oncology (ESMO) in Xiamen, Fujian Province, in September 2019esophageal cancer is a high incidence of cancer in China, and the type of pathology is different from that in Europe and the United States, for patients with advanced stage treatment failure, there is no effective treatment planThe success of escort research is expected to address the urgent need for clinical treatmentZhai Jianjun, deputy general manager and chief medical officer of Jiangsu Hengrui Pharmaceuticals, pointed out that the success of ESCORT research has solved the urgent need for clinical treatment"We will also strengthen communication and close cooperation with regulators to bring this potentially effective treatment to patients as soon as possible." She saidXu Jianming, a researcherthe study and the Fifth Medical Center of the Chinese People's Liberation Army General Hospital, said that for decades, advanced esophageal squamous cancer has been effective only by chemotherapy, while second-line chemotherapy has had very limited effect and fell far short of the expectations of doctors and patientsThe ESCORT study not only exceeds the effect of existing second-line chemotherapy, but also provides a direction for expanding the clinical treatment of esophageal squamous cancer in the futureAnother leading researcher of thestudy, Professor Huang Mirror of the Chinese Academy of Medical Sciences Oncology Hospital, believes that Carreri-Zhudanis, in the second-stage clinical study of advanced esophageal cancer, has proved that compared with traditional chemotherapy, it can effectively improve the total survival time of patients, delay disease progression, bring new treatment opportunities and new hope to patients with advanced esophageal cancer in China, and will enable more patients with esophageal cancer to benefit from the treatment of Karlie Zumaiit is understood that the injection with Carreli Pearl mono-resistance is Hengrui independent research and development of human-derived anti-PD-1 monoclonal antibody, is China's independent intellectual property rights of immunotherapy innovative drugsIn May this year, The indications of Carrelli Pearl mono-resistance for relapsing in refractory classic Hodgkin's lymphoma were approvedAt present, including lymphoma, esophageal cancer, CarreyZumac has been carried out a total of 32 clinical trials of single-drug or combined chemotherapy, a total of nearly 3000 patients in the group, and focus on China's high-risk and difficult to treat tumors, such as liver cancer, stomach cancer, lung cancer, esophageal cancer, nasopharyngeal cancer, etc., aimed at making China's cancer patients benefitAmong them, the clinical study of the first-line treatment of advanced hepatocellular carcinoma in the first-line of Thecarili-Zunadini has been carried out simultaneously in many regions at home and abroad, and is expected to promote the national innovation drug to the international level in the future.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.